Approximately 2 to 3 million women in France live with osteoporosis. Targeted medications can help rebuild bone density and significantly lower fracture risk.
Osteoporosis is a progressive bone disease where density decreases, making bones fragile and prone to fractures. Effective treatment focuses on enhancing bone strength to prevent breaks, which can be life-altering—especially vertebral or hip fractures in older adults.
Post-fracture, many seniors lose independence, and studies show a higher mortality risk following hip fractures.
Diagnosis relies on bone densitometry, a straightforward imaging test.
Multiple reliable methods are available. The gold standard in France is dual-photon X-ray densitometry, which assesses density in the hip or lumbar spine.
This technique is widely used across the country. Quantitative ultrasound at the heel is an emerging, equally painless alternative. Both tests are non-invasive and quick.
In France, costs range from €46 to €183, with partial reimbursement (70% based on €39.96).
Postmenopausal women are most affected, as declining estrogen levels accelerate bone loss. About 2 to 3 million French women are impacted, but risks rise after age 60-65 for some.
Family history is key: If your mother had an osteoporosis-related fracture, prioritize screening. Other factors include early menopause, late puberty, low body weight, long-term corticosteroid use, vitamin D or calcium shortages, immobility, smoking, alcohol excess, and even depression per recent studies.
Yes—one in eight men over 50 develops it, compared to one in three women. Risk factors mirror those in women.
Hormone Replacement Therapy (HRT): For postmenopausal women, HRT slows bone loss, prevents, and treats osteoporosis. It boosts bone density and eases menopause symptoms, with potential benefits against cardiovascular events and Alzheimer's. However, improper use may cause vaginal bleeding, weight gain, breast tenderness, or a slight breast cancer risk increase, per epidemiological data.
Raloxifene: This selective estrogen receptor modulator (SERM) builds bone mass. Clinical studies show a 55% reduction in vertebral fractures after three years, though hip benefits are unproven. It lowers breast cancer risk (unlike HRT), avoids endometrial cancer risk, and improves cholesterol.
Calcium and Vitamin D: Essential from youth for bone health, they enhance other treatments. Aim for 1,000-1,500 mg calcium daily via dairy or supplements; vitamin D from sunlight, fish liver oils, fatty fish, egg yolks, or butter. Many osteoporosis drugs incorporate these.
Ideally, continue for over three years to solidify gains, though adherence can be challenging. After 2-3 years, transition to calcium and vitamin D maintenance. Repeat densitometry two years post-treatment to monitor for recurrence.
Sources:
